Bringing The Next-Generation Of Antibiotics
to win the war against resistant bacteria
Our Vision
Our company
Omnix Medical is a biopharmaceutical company
Founded in 2015, Omnix Medical is developing an arsenal of novel antibiotic agents for the treatment of infections involving drug-resistant bacteria.
Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Our technology
Our exceptional technology offers a first-in-its-class drug
Company News
A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6
A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, a Novel Antimicrobial Peptide Targeting Acinetobacter
Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)
Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).